1-3 of 3
Jay Tanna
Close
Sort by
Journal Articles

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study

Clinical Trials & Observations
Birte Wistinghausen, Keri Toner, Donald A. Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela Chansky, Gloria Pezzella, Lauren Saguilig, Robert J. Hayashi, Harshal Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick Hanley, Michelle L. Hermiston, Carl E. Allen, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1116–1127.
https://doi.org/10.1182/bloodadvances.2023010832
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease

Clinical Trials & Observations
Hannah Kinoshita, Mamatha Mandava, Mariah Jensen-Wachspress, Haili Lang, Elisabeth Joy, Jay Tanna, Chase D. McCann, Samuel O’Brien, Sianna Burnett, Abeer Shibli, Fahmida Hoq, Monica Bhatia, Patrick J. Hanley, Blachy Dávila Saldaña, Kris M. Mahadeo, Catherine M. Bollard, Michael D. Keller, Allistair Abraham
Journal: Blood Advances
Blood Adv (2023) 7 (10): 2105–2116.
https://doi.org/10.1182/bloodadvances.2022008219
Published: 2023
Includes: Supplemental data
Journal Articles

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT

Clinical Trials & Observations
Hannah Kinoshita, Kenneth R. Cooke, Melanie Grant, Maja Stanojevic, C. Russell Cruz, Michael Keller, Maria Fernanda Fortiz, Fahmida Hoq, Haili Lang, A. John Barrett, Hua Liang, Jay Tanna, Nan Zhang, Abeer Shibli, Anushree Datar, Kenneth Fulton, Divyesh Kukadiya, Anqing Zhang, Kirsten M. Williams, Hema Dave, Jeffrey S. Dome, David Jacobsohn, Patrick J. Hanley, Richard J. Jones, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2520–2534.
https://doi.org/10.1182/bloodadvances.2021006831
Published: 2022
Includes: Supplemental data